Citations

Showing 10 of 108119 citations.

Transcriptomic analysis of Streptococcus agalactiae periprosthetic joint infection
Masters, Thao , Greenwood‐Quaintance, Kerryl E. , Johnson, Stephen , Pu, Meng , Cho, Hye-Kyung , Jeraldo, Patricio , Chia, Nicholas , Abdel, Matthew P. , Patel, Robin

Mayo Clinic

No container title available | November 27, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.163803783.32306564/v1 Get It

Although Streptococcus agalactiae periprosthetic joint infection (PJI) is not as prevalent as staphylococcal PJI, invasive S. agalactiae infection has recently increased in incidence. Here, RNA-Seq was used to perform transcriptomic analysis of S. agalactiae PJI using fluid derived from sonication of explanted arthroplasties of subjects with S. agalactiae PJI, with results compared to those of S. agalactiae strain NEM316 grown in vitro. 227 genes with outlier expression were found (164 up-regulated and 63 down-regulated) between PJI sonicate fluid and in vitro conditions. Functional enrichment analysis showed genes involved in mobilome and inorganic ion transport and metabolism to be most enriched. Genes involved in nickel, copper, and zinc transport, were upregulated. Among known virulence factors, cyl operon genes, encoding beta-hemolysin/cytolysin, were consistently highly expressed in PJI versus in vitro. The data presented provide insight into S. agalactiae PJI pathogenesis and may be a useful resource for the identification of novel PJI therapeutics or vaccines against invasive S. agalactiae infections.
Identifying opportunities to advance health equity in interventional cardiology: Structural heart disease
Allana, Salman , Alli, Olueseun, Coylewright, Megan , Horne, Aaron, Ijioma, Nkechinyere , Kadavath, Sabeeda , Pineda, Andrés M. , Sanchez, Carlos E. , Schreiber, Theodore , Shah, Atman P. , Smith, Conrad, Young, Michael N. , Krishnan, Sandeep , Allana, Salman S , Ijioma, Nkechi , Pineda, Andres , Sanchez, Carlos , Suradi, Hussam , Young, Michael , Krishnan, Sandeep K , Alkhouli, Mohamad , Sylvia, Kristyn E.

Mayo Clinic

Catheterization and Cardiovascular Interventions | November 27, 2021 | Volume: 99 | Issue: 4 | Pages: 1165-1171

10.1002/ccd.30021 | PMID 34837459 Get It

AbstractHealth care practices are influenced by variety of factors. These factors that include social determinants, race and ethnicity, and gender not only affect access to health care but can also affect quality of care and patient outcomes. These are a source of health care disparities. This article acknowledges that these disparities exist in getting optimal care in structural heart disease, reviews the literature and proposes steps that can help reduce these disparities on personal and committee levels.
Apheresis medicine in the era of advanced telehealth technologies: An American Society for Apheresis position paper part II: Principles of apheresis medical practice in a 21st century electronic medical practice environment
Linz, Walter J. , Andrzejewski, Chester , Hofmann, Jan , Linz, Walter

Mayo Clinic

Journal of Clinical Apheresis | November 27, 2021 | Volume: 37 | Issue: 1 | Pages: 122-126

10.1002/jca.21951 | PMID 34837406 Get It

Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone
Wetterling, Friedrich , Gaul, Robert , Sheridan, Stephen, Asher, Jennifer L. , Rao, Veena S. , Mahoney, Devin , Mebazaa, Alexandre , Gray, Alastair , Cowie, Martín , Fudim, Marat , McDonald, Kenneth , Damman, Kevin , Cowie, Martin R , Ivey-Miranda, Juan B , Maulion, Christopher , Burkhoff, Daniel , Cox, Zachary L , Butler, Javed , Borlaug, Barry A. , Testani, Jeffrey M.

Mayo Clinic

European Journal of Heart Failure | November 27, 2021 | Volume: 24 | Issue: 3 | Pages: 455-462

10.1002/ejhf.2395 | PMID 34837447 Get It

Aims Remote monitoring of pulmonary artery pressure has reduced heart failure (HF) hospitalizations in chronic HF as elevation of pulmonary artery pressure provides information that can guide treatment. The venous system is characterized by high capacitance, thus substantial increases in intravascular volume can occur before filling pressures increase. The inferior vena cava (IVC) is a highly compliant venous conduit and thus a candidate for early detection of change in intravascular volume. We aimed to compare IVC cross‐sectional area using a novel sensor with cardiac filling pressures during experimental manipulation of volume status, vascular tone, and cardiac function. Methods and results Experiments were conducted in sheep to manipulate volume status (colloid infusion), vascular tone (nitroglycerin infusion) and cardiac function (rapid cardiac pacing). A wireless implantable IVC sensor was validated ex‐vivo and in‐vivo , and then used to measure the cross‐sectional area of the IVC. Right‐ and left‐sided cardiac filling pressures were obtained via right heart catheterization. The IVC sensor provided highly accurate and precise measurements of cross‐sectional area in ex‐vivo and in‐vivo validation. IVC area changes were more sensitive than the corresponding changes in cardiac filling pressures during colloid infusion ( p < 0.001), vasodilatation ( p < 0.001) and cardiac dysfunction induced by rapid pacing ( p ≤ 0.02). Conclusions Inferior vena cava area can be remotely and accurately measured in real time with a wireless implantable sensor. Changes in IVC area are more sensitive than corresponding changes in filling pressures following experimental volume loading and fluid redistribution. Additional research is warranted to understand if remote monitoring of the IVC may have advantages over pressure‐based monitors in HF.
Elevated Expression of the Long Noncoding RNA MAFTRR in Patients with Hashimoto’s Thyroiditis
Peng, Huiyong , Ding, Xiangmei, Xu, Juan, Han, Yue , Yang, Jun, Tang, Xinyi , Wang, Shengjun , Liu, Yingzhao , Xu, Juan, Yang, Jun

Mayo Clinic

Journal of Immunology Research | November 27, 2021 | Volume: 2021 | Issue: No issue available | Pages: 1-11

10.1155/2021/3577011 | PMID 34869781 Get It

Background. Long noncoding RNAs (lncRNAs) represent an important novel class of noncoding RNA molecule greater than 200 nucleotides that play a key role in the regulation of autoimmune diseases. Previous studies have demonstrated that MAFTRR (MAF transcriptional regulator RNA) regulated Th1 cells differentiation by inhibiting the expression of MAF in activated CD4+ T cells. However, the effect of MAFTRR on the pathogenesis of Hashimoto’s thyroiditis (HT) remains unclear. This research was aimed at investigating the expression of MAFTRR in Hashimoto’s thyroiditis (HT) as well as the correlation between MAFTRR and Th1 cells. Methods. Thirty-eight HT patients and thirty-eight healthy controls were enrolled in the study. The proportion of Th1 cells and CD8+IFN-γ+ T cells in peripheral blood mononuclear cells (PBMCs) from these specimens was determined by flow cytometric analysis. The transcript levels of MAFTRR, MAF, and IFNG in PBMCs and thyroid glands were detected by quantitative real-time PCR. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the potential value of MAFTRR in the HT patients. Results. We found that the proportion of circulating Th1 cells and the transcript levels of IFNG were increased in peripheral blood of the HT patients. The transcript levels of MAFTRR were significantly increased in the HT patients and positively correlated with the percentage of Th1 cells and serum levels of antithyroglobulin antibody and antithyroperoxidase antibody. The transcript levels of MAF, a transcription factor that inhibits Th1 cells activity and IFN-γ production, were attenuated in PBMCs from the HT patients. The transcript levels of IFNG had positive and inverse correlations with MAFTRR and MAF expression in PBMCs from the HT patients, respectively. Additionally, a significantly positive correlation between upregulated MAFTRR expression and augmented IFNG expression was revealed in thyroid tissues from the HT patients. ROC curve suggested that MAFTRR could potentially differentiate the HT patients from healthy controls. Conclusion. MAFTRR is significantly augmented in the HT patients and may contribute to the pathogenic role of the Th1 cells response in HT.
Mismatch repair deficiency: The what, how and why it is important
Olave, Maria C. , Graham, Rondell P. , Graham, Rondell P

Mayo Clinic

Genes, Chromosomes and Cancer | November 27, 2021 | Volume: 61 | Issue: 6 | Pages: 314-321

10.1002/gcc.23015 | PMID 34837268 Get It

Abstract The mismatch repair system is a major pathway that functions in the maintenance of genomic integrity. It is involved in mitotic and meiotic recombination, apoptosis, immunoglobulin gene rearrangement, somatic hypermutation, and other processes. Deficiencies in mismatch repair give rise to hypermutability and the phenomenon called microsatellite instability. Detection of deficient mismatch repair function or microsatellite instability is used diagnostically, predictively, and prognostically. Specifically, deficient mismatch repair function is used for screening of Lynch syndrome, determining patients who are likely to respond to immune checkpoint inhibition, and to contributes to an understanding of which cancer patients may pursue a more aggressive clinical course. Microsatellite instability can be evaluated directly by polymerase chain reaction (PCR) or indirectly by assessment of mismatch repair protein expression using immunohistochemistry (IHC), and mismatch repair function using next‐generation sequencing assays which evaluates homopolymer indels. In this article, we provide a concise practical review on mismatch repair deficiency (MMR‐d)/microsatellite instability (MSI), focusing on clinical testing, different testing methods, interpretation of findings, the predictive, and prognostic utility of MSI.
The Great Breast Cancer Screening Conundrum
Desai, Aakash , Mathew, Aju , Desai, Aakash P

Mayo Clinic

Indian Journal of Medical and Paediatric Oncology | November 27, 2021 | Volume: 42 | Issue: 04 | Pages: 376-379

10.1055/s-0041-1731859 Get It

Medulläres Schilddrüsenkarzinom
Kroiß, Matthias , Koehler, Viktoria Florentine , Spitzweg, Christine , Kroiss, Matthias

Mayo Clinic

DMW - Deutsche Medizinische Wochenschrift | November 27, 2021 | Volume: 146 | Issue: 23 | Pages: 1527-1532

10.1055/a-1495-2991 | PMID 34826838 Get It

Was ist neu? Diagnose und Prognose Calcitonin ist ein sensitiver und spezifischer Tumormarker zur Früherkennung und Verlaufskontrolle des MTC. Daneben kommt dem Ultraschall der Schilddrüse eine entscheidende Rolle zu. Rolle des RET-Proto-Onkogens Das medulläre Schilddrüsenkarzinom (MTC) nimmt seinen Ursprung aus den parafollikulären Calcitonin-produzierenden C-Zellen. Es macht nur ca. 3–8 % aller Schilddrüsenkarzinome aus. Aktivierende Mutationen im RET (rearranged during transfection)-Gen liegen bei etwa 25 % der Patienten in der Keimbahn vor, werden aber auch beim sporadischen MTC als somatische Mutationen in ca. 60 % der Fälle beobachtet. Bei metastasierter Erkrankung findet sich in 90 % eine RET-Mutation. RET-Mutationen gelten als Treibermutationen und schließen weitere Treibermutationen weitestgehend aus. Seltener sind somatische Mutationen der RAS-Gene. Chirurgische Therapie Die chirurgische Resektion ist bis heute der einzige kurative Therapieansatz. Entscheidend für eine frühzeitige Diagnosestellung ist die Bestimmung des Serum-Calcitonins bei Nachweis von Schilddrüsenknoten. Die chirurgische Therapie steht auch bei der Behandlung lokoregionärer Rezidive oder lokal angehbarer Metastasen im Zentrum. Systemtherapie Bei irresektabel fortgeschrittener und progredienter Erkrankung mit signifikanter Tumorlast kann eine systemische Therapie erforderlich werden. Neuerdings ist die Kenntnis einer RET-Mutation im Tumorgewebe therapeutisch relevant, da mit den selektiven RET-Inhibitoren Selpercatinib und zukünftig Pralsetinib neue, effektive und gut verträgliche Systemtherapien zur Verfügung stehen. Ihr Einsatz ist nach Vortherapie mit einem der Multityrosinkinase-Inhibitoren Vandetanib oder Cabozantinib zugelassen und wird derzeit in der Erstlinientherapie in klinischen Studien untersucht.
Outpatient Issues in Neurology
Stitt, Derek , Safdieh, Joseph E.

Mayo Clinic

Seminars in Neurology | November 26, 2021 | Volume: 41 | Issue: 06 | Pages: 632-632

10.1055/s-0041-1735894 | PMID 34826867 Get It

The Outpatient Approach to Dizziness
Brune, Anthony J., Eggenberger, Eric , Eggenberger, Eric R

Mayo Clinic

Seminars in Neurology | November 26, 2021 | Volume: 41 | Issue: 06 | Pages: 771-780

10.1055/s-0041-1726369 | PMID 34826878 Get It

AbstractThe evaluation of the dizzy patient is complicated by many common pitfalls. The patient's description of symptoms and the standard neurologic examination are often nonspecific or unrevealing, and neuroimaging is most often normal. Over the past several years, research has demonstrated that a refocusing of history taking results in more reliable and diagnostically helpful information. This can guide a targeted expansion of the exam, often with an emphasis on eye movements.